Becker's Healthcare September 27, 2024
Alexandra Murphy

AbbVie’s tavapadon has demonstrated positive results as a monotherapy for early Parkinson’s disease, according to a Sept. 26 news release from the drugmaker.

Three notes:

  1. The phase 3 Tempo-1 trial for tavapadon, a dopamine receptor partial agonist, demonstrated significant efficacy as a monotherapy in early Parkinson’s disease. Patients receiving the drug at doses of 5 milligrams and 15 milligrams showed significant reductions in the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale.
  2. In addition to the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Clinical Trials, Pharma, Pharma / Biotech, Trends
Related Articles:
Halozyme Pulls €2B Acquisition Bid as Evotec Commits to Standalone Strategy
More than half of US adults could benefit from GLP-1 medications, researchers find
RNA editing is the next frontier in gene therapy—here's what you need to know
Rand roadblock: Biotech bill’s uncertain future
How Digital Chemistry Will Improve Cross-Functional Collaboration In The Biopharma Industry

Share This Article